An observational study in Liver Cirrhoses, sponsored by Institute of Liver and Biliary Sciences, India. Status unknown at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-09-03.
Sponsored by Institute of Liver and Biliary Sciences, India · Observational
To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease
1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 151 across 587 observational studies indexed under Liver Cirrhosis.
Browse Liver Cirrhosis studies →Institute of Liver and Biliary Sciences, India is the lead sponsor of 296 studies on the registry; 84 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All Covid-19 patients with or without liver disease
Exclusion Criteria:
Covid-19 with liver disease
Other: no intervention
Covid-19 without liver disease
Other: no intervention
no intervention
Spontaneous recovery or death in both groups
Time frame: 90 days
Severity of prior as well as present decompensation in both groups
Time frame: 90 days
Duration of prior as well as present decompensation in both groups
Time frame: 90 days
Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups
Time frame: 90 days
Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups
Time frame: 90 days
Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups
Time frame: 90 days
Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups
Time frame: 90 days
Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.
Time frame: 90 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Liver and Biliary Sciences, India